TSRX mgt shot themselves in the foot; with SEC investigations, multiple dilution, claims of superiority unsubstantiated by the data, perpetual shelf registrations, un-ending insider sales, no news, no new partnerships, etc etc etc.
Other developmental antibiotic companies are flying high at new all-time highs (e.g. PYMX, NBY) while TSRX freefalls to new lows.
The other 2 companies I don't think rival TSRX. Polymedix is only in early trials of the defensin analog for IV use. TSRX is cheaper than Polymedix on enterprise valuation (market cap less cash) and is much further along on getting to market.
The other one is topical from NBY.
The TSRX drug can be used to treat infections that are resistant to Zyvox.
I think we keep building a position as this one sleeps.
This is much, much better than CHTP. The vote was only 7-4-1 for CHTP drug. I approval a sure thing?
Kitty will spread news to friends on TSRX when the time is right (Dr. Kitty does great DD analysis). For now we keep silent and accumulate. Just think where we will be in 1 year. Most will not wait that long and are chasing the flavor of the day or PDUFA plays. JMO